Generic Product News (November 2016)

Publication
Article
Pharmacy TimesNovember 2016 Cough, Cold, & Flu
Volume 82
Issue 11

Read about the new generic products featured in November.

OSELTAMIVIR PHOSPHATEMARKETED BY: Natco Pharma, Ltd COMPARE TO: Tamiflu (Roche)

INDICATION: Natco Pharma, Ltd, has announced final FDA approval of an Abbreviated New Drug Application for Oseltamivir Phosphate, a generic version of Roche’s Tamiflu oral capsules. Oseltamivir Phosphate is indicated for treating the flu in individuals 2 weeks and older who have had flu symptoms for no more than 2 days. The product can also reduce the chance of getting the flu in individuals 1 year and older.

DOSAGE FORM: Capsules: 30, 45, and 75 mg

FOR MORE INFORMATION: natcopharma.co.in

OXICONAZOLE NITRATE CREAM, 1%MARKETED BY: Taro Pharmaceuticals USA, Inc

COMPARE TO: Oxistat (PharmaDerm)

INDICATION: Taro Pharmaceuticals has announced the launch of Oxiconazole Nitrate Cream, which is indicated for the topical treatment of infections due to tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum. The product is also indicated for the topical treatment of tinea (pityriasis) versicolor due to Malassezia furfur.

DOSAGE FORM: Cream, 1%

FOR MORE INFORMATION: taro.com

DULOXETINEMARKETED BY: Camber Pharmaceuticals, Inc

COMPARE TO: Cymbalta (Eli Lilly)

INDICATION: Camber Pharmaceuticals has announced the launch of Duloxetine, its generic version of Cymbalta capsules by Eli Lilly. Duloxetine is indicated for treating depression and anxiety.

DOSAGE FORM: Capsules: 20, 30, and 60 mg

FOR MORE INFORMATION: camberpharma.com

DICLOFENAC SODIUM GEL, 3%MARKETED BY: Glenmark Pharmaceuticals, Inc

COMPARE TO: Solaraze Gel, 3%

INDICATION: Glenmark Pharmaceuticals has received final FDA approval for Diclofenac Sodium Gel, 3%, its generic version of Solaraze Gel, 3%, by Fougera Pharmaceuticals, Inc. Diclofenac Sodium Gel, 3%, is indicated for the topical treatment of actinic keratoses. Sun avoidance is indicated during therapy.

DOSAGE FORM: Gel: 3%

FOR MORE INFORMATION: glenmarkpharma.com

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
© 2024 MJH Life Sciences

All rights reserved.